Efficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration
2.
Emergency Medicine Unit, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
3.
Aston Medical School, Faculty of Health & Life Sciences, Aston University, Birmingham, United Kingdom
4.
Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
5.
Department of Anaesthesia and Pain Service, Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong, China
6.
Department of Medicine, Cleveland Clinic Foundation, Cleveland, USA
7.
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China
8.
Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil
9.
Kent and Medway Medical School, Canterbury, Kent, United Kingdom
Funds:
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
None *The authors contributed equally to this manuscript
OBJECTIVES To assess the effect of vasopressin, steroid and epinephrine (VSE) combination therapy on return of spontaneous circulation (ROSC) after in-hospital cardiac arrest (IHCA), and test the conclusiveness of evidence using trial sequential analysis (TSA).METHODS The systematic search included PubMed, EMBASE, Scopus, and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) that included adult patients with IHCA, with at least one group receiving combined VSE therapy were selected. Data was extracted independently by two reviewers. The main outcome of interest was ROSC. Other outcomes included survival to hospital discharge or survival to 30 and 90 days, with good neurological outcomes.RESULTS We included a total of three RCTs (n = 869). Results showed that VSE combination therapy increased ROSC (risk ratio = 1.41; 95% CI: 1.25-1.59) as compared to placebo. TSA demonstrated that the existing evidence is conclusive. This was also validated by the alpha-spending adjusted relative risk (1.32 [1.16, 1.49], P < 0.0001). Other outcomes could not be meta-analysed due to differences in timeframe in the included studies.CONCLUSIONS VSE combination therapy administered in cardiopulmonary resuscitation led to improved rates of ROSC. Future trials of VSE therapy should evaluate survival to hospital discharge, neurological function and long-term survival.
Sinha SS, Sukul D, Lazarus JJ, et al. Identifying Important Gaps in Randomized Controlled Trials of Adult Cardiac Arrest Treatments: A Systematic Review of the Published Literature. Circ Cardiovasc Qual Outcomes 2016; 9: 749−756. doi: 10.1161/CIRCOUTCOMES.116.002916
[2]
Angelos MG, Butke RL, Panchal AR, et al. Cardiovascular response to epinephrine varies with increasing duration of cardiac arrest. Resuscitation 2008; 77: 101−110. doi: 10.1016/j.resuscitation.2007.10.017
[3]
Lindner KH, Brinkmann A, Pfenninger EG, et al. Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth Analg 1993; 77: 427−435.
[4]
Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004; 2: 1−12. doi: 10.2174/1570161043476483
[5]
Chan JSK, Harky A. Trial sequential analysis in meta-analyses: a clinically oriented approach with real-world example. J Thorac Cardiovasc Surg 2021; 162: 167−173. doi: 10.1016/j.jtcvs.2020.06.063
[6]
Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA 2013; 310: 270−279. doi: 10.1001/jama.2013.7832
[7]
Andersen LW, Isbye D, Kjaergaard J, et al. Effect of vasopressin and methylprednisolone vs placebo on return of spontaneous circulation in patients with in-hospital cardiac arrest: a randomized clinical trial. JAMA 2021; 326: 1586−1594. doi: 10.1001/jama.2021.16628
[8]
Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med 2009; 169: 15−24. doi: 10.1001/archinternmed.2008.509
[9]
Shah K, Mitra AR. Use of corticosteroids in cardiac arrest-a systematic review and meta-analysis. Crit Care Med 2021; 49: e642−e650. doi: 10.1097/CCM.0000000000004941
[10]
Liu B, Zhang Q, Li C. Steroid use after cardiac arrest is associated with favourable outcomes: a systematic review and meta-analysis. J Int Med Res 2020; 48: 300060520921670.
[11]
Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 2017; 17: 39. doi: 10.1186/s12874-017-0315-7
[12]
Yan S, Gan Y, Jiang N, et al. The global survival rate among adult out-of-hospital cardiac arrest patients who received cardiopulmonary resuscitation: a systematic review and meta-analysis. Crit Care 2020; 24: 61. doi: 10.1186/s13054-020-2773-2
Figure 1. PRISMA flow diagram detailing the search strategy and study selection process for this systematic review and meta-analysis on the efficacy of vasopressin-steroid-epinephrine combination therapy for in-hospital cardiac arrest resuscitation.
Figure 2. Risk of bias (quality) assessment of randomized controlled trials using Cochrane Risk of Bias 2 tool.
Figure 3. Risk ratios of randomized controlled trials comparing vasopressin-steroid-epinephrine combination therapy to placebo using a random-effects model with Mantel-Haenszel (M-H) weighting for return of spontaneous circulation (ROSC).